Short Interest in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Increases By 13.8%

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 6,510,000 shares, a growth of 13.8% from the September 15th total of 5,720,000 shares. Based on an average daily volume of 381,900 shares, the short-interest ratio is currently 17.0 days.

Analyst Ratings Changes

A number of research analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Monday, October 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th.

KalVista Pharmaceuticals Stock Up 2.2 %

KALV opened at $11.98 on Wednesday. The company’s 50-day moving average price is $11.82 and its 200 day moving average price is $12.07. KalVista Pharmaceuticals has a fifty-two week low of $7.21 and a fifty-two week high of $16.88. The firm has a market cap of $505.41 million, a price-to-earnings ratio of -3.52 and a beta of 0.89.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.04. Research analysts anticipate that KalVista Pharmaceuticals will post -3.35 earnings per share for the current year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Christopher Yea sold 7,102 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $85,295.02. Following the sale, the insider now directly owns 84,467 shares in the company, valued at $1,014,448.67. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Paul K. Audhya sold 2,135 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $12.40, for a total value of $26,474.00. Following the sale, the insider now owns 83,745 shares in the company, valued at approximately $1,038,438. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Christopher Yea sold 7,102 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $85,295.02. Following the transaction, the insider now directly owns 84,467 shares in the company, valued at $1,014,448.67. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,804 shares of company stock valued at $372,112. Insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in KALV. nVerses Capital LLC acquired a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter worth about $25,000. EntryPoint Capital LLC bought a new stake in shares of KalVista Pharmaceuticals during the first quarter valued at approximately $92,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of KalVista Pharmaceuticals by 101.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 8,024 shares of the specialty pharmaceutical company’s stock valued at $95,000 after buying an additional 4,043 shares during the last quarter. Entropy Technologies LP acquired a new position in shares of KalVista Pharmaceuticals during the first quarter worth approximately $121,000. Finally, SG Americas Securities LLC bought a new position in KalVista Pharmaceuticals in the 3rd quarter worth approximately $153,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.